Published on 27/12/2025
Best Practices for Long-Term Storage of Biological Samples in Rare Disease Trials
Why Long-Term Sample Storage Is Critical in Rare Disease Research
Long-term biological sample storage is an essential component of rare disease clinical trials. Due to the small number of patients and the progressive nature of many rare diseases, biospecimens often represent irreplaceable data sources. Properly stored samples may be reanalyzed years later for biomarker discovery, regulatory re-submissions, or personalized medicine approaches.
Rare disease research also increasingly involves genomic, proteomic, and metabolomic analyses that may require future access to well-preserved blood, tissue, DNA, RNA, or cerebrospinal fluid (CSF). Maintaining sample integrity and traceability over extended periods—often exceeding 10 years—is therefore not only scientifically beneficial but also a regulatory expectation under GCP and ISO 20387 biobanking standards.
Sample Types and Storage Conditions in Rare Disease Studies
Biological materials collected in rare disease trials can include:
- Whole blood and plasma – often stored at -80°C
- DNA/RNA isolates – stored at -20°C to -80°C depending on stabilization
- Serum – stored at -20°C or -80°C for long-term preservation of proteins
- CSF, tissue biopsies, or skin fibroblasts – frequently stored in cryogenic freezers at -150°C or liquid nitrogen (-196°C)
Correct sample aliquoting, label
Biobank Infrastructure and Storage Facility Considerations
Biobanking for rare disease studies must meet rigorous operational and regulatory standards. Core infrastructure elements include:
- Ultra-low temperature (ULT) freezers with 24/7 monitoring
- Redundant power supply and backup generators
- Centralized temperature monitoring systems with alarms and audit trails
- Controlled access with restricted personnel entry
- Validated cleaning and maintenance protocols
For multinational trials, a distributed storage model may be used, with regional biorepositories storing aliquots to reduce transit times and risks. These sites must be pre-qualified and audited for compliance with ISO 20387 and GCP sample handling guidelines.
Labeling, Coding, and Chain of Custody
Sample mislabeling is a major source of regulatory inspection findings. Sponsors must implement standardized procedures for:
- Unique Sample Identifiers (USIs) – linked to anonymized subject IDs
- Barcode-based tracking – integrated with Laboratory Information Management Systems (LIMS)
- Label durability – resistant to freezing, condensation, and chemical exposure
- Documentation of all sample transfers – chain of custody logs from site to storage facility
One EMA inspection report highlighted a deviation where patient samples in a mitochondrial disorder trial were mislabeled due to manual transcription errors—compromising the biomarker substudy. Implementing LIMS with handheld barcode scanners could have prevented this issue.
Sample Retention and Reuse Policies
Retention policies for rare disease samples should be aligned with trial protocols, informed consent documents, and regulatory requirements. Common durations include:
- 5–15 years for regulatory traceability
- Indefinite storage if consent permits future use in related studies
- Mandatory destruction post-study if opted by participant
Consent documentation must clearly outline whether samples may be used for genetic research, shared with other researchers, or transferred to commercial biobanks. In rare disease trials, families may be especially sensitive to these aspects, given the personal and generational stakes involved.
Cold Chain Logistics and Sample Shipment
Many rare disease trials involve international sample shipments from remote or rural clinics to central labs. Best practices include:
- Use of validated shipping containers with temperature loggers
- Clear SOPs for pre-freeze handling and packaging
- Courier selection based on time-in-transit reliability
- Immediate temperature and integrity checks upon receipt
In a lysosomal storage disorder trial spanning India, Brazil, and Canada, failure to meet cold chain compliance led to the rejection of 7% of baseline samples—resulting in missed pharmacodynamic analyses for key endpoints. Establishing a central lab hub in each continent helped solve the issue.
Implementing Sample Inventory and Audit Systems
Maintaining inventory integrity over 10+ years requires robust systems for:
- Batch tracking and expiration alerts
- Destruction documentation with witness verification
- Audit trails for every sample movement or thaw event
- Periodic reconciliation between physical inventory and database
These processes ensure regulatory preparedness and support seamless sample recall in case of reanalysis, assay validation, or regulatory queries.
Conclusion: A Strategic Asset for Future-Ready Rare Disease Research
Long-term sample storage is far more than a logistical task—it is a strategic pillar of rare disease research. Properly preserved and tracked biological materials can enable decades of scientific discovery, regulatory defense, and therapeutic innovation. By investing in compliant biobanking infrastructure and globally harmonized SOPs, sponsors can turn today’s samples into tomorrow’s breakthroughs.
As clinical trial designs evolve and precision medicine becomes mainstream, the value of well-managed rare disease biospecimens will only grow.